QUOTE AND NEWS
FiercePharma  Sep 17  Comment 
Analysts have been waiting--and waiting--for drugmakers to realize the growth they've predicted for the obesity market. And with a couple of pharma companies preparing to pony up R&D and marketing resources for their obesity products, it could...
FierceBiotech  Sep 17  Comment 
In the midst of its first major foray into treating obesity, Novo Nordisk is liking what it sees in the space, and now the Danish giant plans to hire hundreds of researchers in a gambit to develop new treatments for the global scourge.
Reuters  Sep 16  Comment 
Portugal's Novo Banco, the successor to Banco Espirito Santo (BES) after a state rescue, will likely attract bids from foreign banks, a partner at U.S. investment bank...
FierceBiotech  Sep 16  Comment 
Novo Nordisk bolstered its better-late-than-never case to win FDA approval for a new long-acting insulin, as the drug, Tresiba, met its main goals in a study on children with Type 1 diabetes.
Reuters  Sep 16  Comment 
(Updates Kuwait Foods; Adds Eagle Merchant, Novo Banco, Blackstone Group, Citadele, Entropic Communications, Phoenix Services, Blackstone Group, Atlantic Power, Energy Future, Sibur Holding, Roche...
MarketWatch  Sep 15  Comment 
A previous version of the European stock mover story published on Sept. 12 has been revised to specify that it was an FDA advisory panel and not the FDA that recommended approval of the Novo Nordisk drug.
Clusterstock  Sep 15  Comment 
By Andrei Khalip LISBON (Reuters) - Portuguese Prime Minister Pedro Passos Coelho stood by government policy toward the remains of failed Banco Espirito Santo (BES) on Monday, saying a quick sale of its successor Novo Banco was necessary to...
TheStreet.com  Sep 15  Comment 
LISBON, Portugal -- The Bank of Portugal has appointed a new senior management team to run Novo Banco, a bank that the government wants to sell and recoup the 3.9 billion euros ($5 billion) taxpayers provided to resolve Portugal's biggest...





You may also be interested in articles related to Novo Nordisk A/S (NVO):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki